Sign in

@solvingms.bsky.social

@solvingms.bsky.social
156 followers 140 following 10 posts

To fund scientific and/or medical research and to advocate for people with Multiple Sclerosis (MS). #SolvingMS www.solvingms.org Research Database solvingms.org/research-database

PostsRepliesMedia
Reposted by @solvingms.bsky.social
KStenhouse🇨🇦 @klstenhouse.bsky.social · 21/11/2024
Yesterday’s micro-live @themsgym.bsky.social It’s not JUST our hip flexors that are weak, #feedforMSfolk. It starts with our intrinsic kinetic chain. MS doesn’t just hit at one foot, or hand and foot - it’s lesion and down! #neuroplasticity #neurorehab #themsgym www.youtube.com/watch?v=lAHP...
youtube.com
LIVE TRAINING - Hip Flexor Strengthening With Coach T
YouTube video by The MS Gym
251
Reposted by @solvingms.bsky.social
KStenhouse🇨🇦 @klstenhouse.bsky.social · 22/11/2024
Thank you for hearing us, Dr. Giovanonni. #MS peeps, please encourage Dr. G. To join Bluesky. This will be an interesting follow: #covid #longcovid #antivirals #TAF #vemliidy #valacyclovir #bcelldepletion “Long Covid and it’s relationship to MS” gavingiovannoni.substack.com/p/long-covid...
gavingiovannoni.substack.com
Long COVID and its relationship to MS
If intermittent EBV reactivation drives long COVID and MS, it should respond to EBV antiviral strategies. I am aware that many pwMS have started taking antivirals off-label to manage their MS ....
143
Reposted by @solvingms.bsky.social
KStenhouse🇨🇦 @klstenhouse.bsky.social · 22/11/2024
“Autologous Epstein–Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis” November 19, 2024 onlinelibrary.wiley.com/doi/full/10....
Objectives, methods, results, conclusion for Clinical & Translational ImmunologyVolume 13, Issue 11 e70015
001
Reposted by @solvingms.bsky.social
KStenhouse🇨🇦 @klstenhouse.bsky.social · 16/11/2024
There is some data that the acyclovir prodrug #valacyclovir (which I take to halt ebv reactivations) is more effective than #guanasineanalogue antivirals. Better results may come in a trial of late onset #MS or secondary MSers. Viral control ability depleted. 1/2 pubmed.ncbi.nlm.nih.gov/38131621/
pubmed.ncbi.nlm.nih.gov
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis - PubMed
No significant effect of famciclovir on EBV shedding was seen in this small pilot study. Given the low numbers, a small effect of famciclovir cannot be excluded. Salivary EBV shedding in this natalizu...
112
@solvingms.bsky.social @solvingms.bsky.social · 17/11/2024
The BEHIND-MS project introduces the project’s objectives and groundbreaking research efforts. This five-year European research initiative is focused on understanding the role of the EBV in the onset and progression of MS. #EBVcausesMS youtu.be/LvbXvLLsVLw
youtu.be
BEHIND-MS: Exploring the Link Between Epstein-Barr Virus and Multiple Sclerosis
YouTube video by EMSP Brussels
171